Roche was unable to shorten the treatment duration in their ACCELERATE trial. 16 weeks of treatment with SOC saw lower SVR rates and higher relapse rates. As far as I know 24 weeks of treatment is the standard.
After analyzing ACCELERATE trial data, Roche announced back in 2008 that the European Commission has approved a shortened, 16-week course of treatment with SOC for certain hepatitis C patients (genotype 2/3 who have low virus levels before starting treatment, and who show a rapid virological response:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.